Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial

Barry John Debenham Wright; David Sims; Siobhan Smart; Ahmed Alwazeer; Ben Alderson-Day; Victoria Allgar; Clare Whitton; Heather Tomlinson; Sophie Bennett; Jenni Jardine; Nicola McCaffrey; Charlotte Leyland; Christine Jakeman; Jeremy Miles

doi:10.1007/s10803-010-1036-5

Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial

Barry John Debenham Wright, David Sims, Siobhan Smart, Ahmed Alwazeer, Ben Alderson-Day, Victoria Allgar, Clare Whitton, Heather Tomlinson, Sophie Bennett, Jenni Jardine, Nicola McCaffrey, Charlotte Leyland, Christine Jakeman, Jeremy Miles

The Hull York Medical School

Research output: Contribution to journal › Article › peer-review

Abstract

Twenty-two children with autism spectrum disorders who had not responded to supported behaviour management strategies for severe dysomnias entered a double blind, randomised, controlled crossover trial involving 3 months of placebo versus 3 months of melatonin to a maximum dose of 10 mg. 17 children completed the study. There were no significant differences between sleep variables at baseline. Melatonin significantly improved sleep latency (by an average of 47 min) and total sleep (by an average of 52 min) compared to placebo, but not number of night wakenings. The side effect profile was low and not significantly different between the two arms.

Original language	English
Pages (from-to)	175-84
Number of pages	10
Journal	Journal of Autism and Developmental Disorders
Volume	41
Issue number	2
DOIs	https://doi.org/10.1007/s10803-010-1036-5
Publication status	Published - Feb 2011

Keywords

Adolescent
Central Nervous System Depressants
Child
Child Development Disorders, Pervasive
Child, Preschool
Cross-Over Studies
Double-Blind Method
Female
Humans
Male
Melatonin
Questionnaires
Sleep Disorders
Treatment Outcome

Access to Document

10.1007/s10803-010-1036-5

Cite this

Wright, B. J. D., Sims, D., Smart, S., Alwazeer, A., Alderson-Day, B., Allgar, V., Whitton, C., Tomlinson, H., Bennett, S., Jardine, J., McCaffrey, N., Leyland, C., Jakeman, C., & Miles, J. (2011). Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. Journal of Autism and Developmental Disorders, 41(2), 175-84. https://doi.org/10.1007/s10803-010-1036-5

@article{875f9442c09847fa8a96f7b8cdf2a176,

title = "Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial",

abstract = "Twenty-two children with autism spectrum disorders who had not responded to supported behaviour management strategies for severe dysomnias entered a double blind, randomised, controlled crossover trial involving 3 months of placebo versus 3 months of melatonin to a maximum dose of 10 mg. 17 children completed the study. There were no significant differences between sleep variables at baseline. Melatonin significantly improved sleep latency (by an average of 47 min) and total sleep (by an average of 52 min) compared to placebo, but not number of night wakenings. The side effect profile was low and not significantly different between the two arms.",

keywords = "Adolescent, Central Nervous System Depressants, Child, Child Development Disorders, Pervasive, Child, Preschool, Cross-Over Studies, Double-Blind Method, Female, Humans, Male, Melatonin, Questionnaires, Sleep Disorders, Treatment Outcome",

author = "Wright, {Barry John Debenham} and David Sims and Siobhan Smart and Ahmed Alwazeer and Ben Alderson-Day and Victoria Allgar and Clare Whitton and Heather Tomlinson and Sophie Bennett and Jenni Jardine and Nicola McCaffrey and Charlotte Leyland and Christine Jakeman and Jeremy Miles",

year = "2011",

month = feb,

doi = "10.1007/s10803-010-1036-5",

language = "English",

volume = "41",

pages = "175--84",

journal = "Journal of Autism and Developmental Disorders",

publisher = "Springer",

number = "2",

}

Wright, BJD, Sims, D, Smart, S, Alwazeer, A, Alderson-Day, B, Allgar, V, Whitton, C, Tomlinson, H, Bennett, S, Jardine, J, McCaffrey, N, Leyland, C, Jakeman, C & Miles, J 2011, 'Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial', Journal of Autism and Developmental Disorders, vol. 41, no. 2, pp. 175-84. https://doi.org/10.1007/s10803-010-1036-5

Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. / Wright, Barry John Debenham; Sims, David; Smart, Siobhan et al.
In: Journal of Autism and Developmental Disorders, Vol. 41, No. 2, 02.2011, p. 175-84.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies

T2 - a randomised controlled crossover trial

AU - Wright, Barry John Debenham

AU - Sims, David

AU - Smart, Siobhan

AU - Alwazeer, Ahmed

AU - Alderson-Day, Ben

AU - Allgar, Victoria

AU - Whitton, Clare

AU - Tomlinson, Heather

AU - Bennett, Sophie

AU - Jardine, Jenni

AU - McCaffrey, Nicola

AU - Leyland, Charlotte

AU - Jakeman, Christine

AU - Miles, Jeremy

PY - 2011/2

Y1 - 2011/2

N2 - Twenty-two children with autism spectrum disorders who had not responded to supported behaviour management strategies for severe dysomnias entered a double blind, randomised, controlled crossover trial involving 3 months of placebo versus 3 months of melatonin to a maximum dose of 10 mg. 17 children completed the study. There were no significant differences between sleep variables at baseline. Melatonin significantly improved sleep latency (by an average of 47 min) and total sleep (by an average of 52 min) compared to placebo, but not number of night wakenings. The side effect profile was low and not significantly different between the two arms.

AB - Twenty-two children with autism spectrum disorders who had not responded to supported behaviour management strategies for severe dysomnias entered a double blind, randomised, controlled crossover trial involving 3 months of placebo versus 3 months of melatonin to a maximum dose of 10 mg. 17 children completed the study. There were no significant differences between sleep variables at baseline. Melatonin significantly improved sleep latency (by an average of 47 min) and total sleep (by an average of 52 min) compared to placebo, but not number of night wakenings. The side effect profile was low and not significantly different between the two arms.

KW - Adolescent

KW - Central Nervous System Depressants

KW - Child

KW - Child Development Disorders, Pervasive

KW - Child, Preschool

KW - Cross-Over Studies

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Male

KW - Melatonin

KW - Questionnaires

KW - Sleep Disorders

KW - Treatment Outcome

UR - http://www.scopus.com/inward/record.url?scp=78751641576&partnerID=8YFLogxK

U2 - 10.1007/s10803-010-1036-5

DO - 10.1007/s10803-010-1036-5

M3 - Article

C2 - 20535539

VL - 41

SP - 175

EP - 184

JO - Journal of Autism and Developmental Disorders

JF - Journal of Autism and Developmental Disorders

IS - 2

ER -

Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial

Abstract

Keywords

Access to Document

Other files and links

Cite this